Introduction
B-chronic lymphocytic leukemia (B-CLL) cell is defined by the accumulation in the periphery and the bone marrow of slowly dividing long-lived CD5 þ B cells. This disease, the most frequent adult leukemia in Western countries, is heterogeneous and results mainly from a failure of cells to undergo apoptosis rather than by excessive cellular proliferation, as highlighted by an impaired balance between anti-and proapoptotic molecules such as Bcl-2 and Bax. In addition to genetic or epigenetic modifications that may alter their intrinsic survival capacities, interactions of neoplastic B cells with their environment, like cytokines or stroma, may enhance their resistance to apoptosis (Caligaris-Cappio and Hamblin, 1999; Kipps, 2003) . Chemokines are low-molecular-weight molecules primarily involved in leukocyte trafficking. Physiological classification allows to distinguish between inflammatory chemokines, produced in inflamed tissues and specialized for the recruitment of effector cells, and homeostatic chemokines constitutively produced within discrete microenvironments and involved in maintaining physiological trafficking (von Andrian and Mackay, 2000; Moser and Loetscher, 2001) . It is now well admitted that chemokines, in addition to trafficking, have much broader effects on their target cells, like cell growth, differentiation and survival/apoptosis (Luther and Cyster, 2001; Moser and Loetscher, 2001 ). However, their role in cell survival is still controversial in some cell types. For example, CXCL12 (previously known as the a-chemokine stromal-derived factor-1, SDF-1a) has been shown to enhance hematopoietic progenitor cell survival (Hodohara et al., 2000; Lataillade et al., 2002; Lee et al., 2002) , whereas other studies showed no effect on survival (Majka et al., 2000; Glimm et al., 2002) . On T cells, CXCL12 was shown to either promote cell survival (Suzuki et al., 2001) or induce apoptosis (Colamussi et al., 2001) . Trafficking of leukemic cells between blood and microenvironments (that is bone marrow or secondary lymphoid organs) allows them to interact sequentially and/or simultaneously with several homeostatic chemokines via expression of a specific set of receptors.
Thus, an important question is whether chemokines, in addition to regulating leukemic cell trafficking, provide survival signals to these cells. In this study, we have investigated the role of the homeostatic chemokines, CXCL12, CCL21, CCL19 and CXCL13, in B-CLL cell survival. We show that these chemokines provide survival signals to leukemic cells by activating the phosphorylation of mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK)1/ 2 and p90RSK, and of Akt and its effectors GSK3 and FOXO3a. The critical role of FOXO3a in both spontaneous and chemokine-induced B-CLL cell survival was further demonstrated using the transfection of either a constitutively active FOXO3a mutant or FOXO3a siRNA in primary leukemic cells. Our data emphasize the role of chemokines in B-CLL cell resistance to apoptosis and provide evidence that FOXO3a is a key mediator of this process.
Results

Homeostatic chemokines increase B-CLL cells survival
The effect of homeostatic chemokines on B-CLL cell survival was first investigated on B cells purified from 26 patients ( Table 1 ). All patients included in this study expressed on their B cells the chemokine receptors CXCR4 (CXCL12 receptor), CCR7 (CCL19/CCL21 receptor) and CXCR5 (CXCL13 receptor). Figure 1a shows an example of the measurement of cell survival performed in one patient. Numbers in each quadrant, counter clockwise from the lower left quadrant, indicate the percentage of living, apoptotic and necrotic cells, respectively. Chemokine concentrations were determined after a dose response experiment performed on three patients (Figure 1b ). Effects on cell survival from the 26 patients of this study for each chemokine and additional treatments are shown in Figure 1c . 4% (13.8-79 .0%) in cells incubated with anti-BCR antibodies. Differences between untreated and activated cells were statistically significant, and no statistical differences were observed between cells treated with chemokines and PMA or anti-BCR antibodies. In addition, the increase of cell survival was observed on a very large majority of patients. After 3 days of incubation, an increase of cell survival was observed in all cases in the presence of CXCL12 but one with the other chemokines. Thus, a very high proportion of patients responded to chemokines in just one direction. Note that spontaneous cell survival at 72 h was also decreased in the presence of both Ly294002 (Po0.001, 21 patients tested) and UO126 (Po0.001, 21 patients tested; Figure 1c ). By contrast, chemokines did not increase survival of peripheral normal blood B cells isolated from five healthy volunteers and cultured for 72 h in the same conditions (Figure 1d ).
In CLL, cell survival induced by chemokines is PI3K and ERK-dependent Purified leukemic cells were activated for 5 min by chemokines or PMA (Figure 2a ). Immunoblot analysis Mut  138  179  141  14  M  84  IV  C  5/5  9  Pos  NA  100  225  59  15  M  68  0  A  5/5  20  Neg  NA  130  86  113  16  M  63  I  A  4/5  1  Pos  Unmut  302  384  315  17  M  72  0  A  5/5  58  Pos  Unmut  132  320  100  18  F  74  0  A  5/5  3  Pos  Mut  164  293  159  19  M  78  III  C  5/5  96  Pos  NA  99  NA  139  20  F  86  II  B  5/5  4  Neg  NA  124  NA  63  21  M  72  0  A  5/5  2  Pos  Mut  140  NA  221  22  M  64  IV  C  5/5  79  Pos  NA  36  NA  24  23  M  69 Chemokines, FOXO3a and B-CLL M Ticchioni et al using antibodies against phosphorylated Akt, ERK1/2 or p90RSK show that all the homeostatic chemokines tested induced their phosphorylation. The kinetics of phosphorylation was studied after activation of purified leukemic cells for different periods of time by CXCL12. Phosphorylation appears as early as 1 min after activation and was still present 30 min later (Figure 2b ). The implication of phosphatidylinositol 3-kinase (PI3K) in the activation of Akt was demonstrated by cell preincubation with the PI3K inhibitor Ly294002, before chemokine stimulation. The inhibition of Akt phosphorylation induced by chemokines, but not by PMA, suggested that in chronic lymphocytic leukemia (CLL), PI3K is a major component of Akt activation by chemokines (Figure 2a and b) . The phosphorylation of ERK1/2 and p90RSK, a downstream kinase of ERK1/ 2, was also induced in a time dependent manner by CXCL12 ( Figure 2b ) and by other homeostatic chemokines ( Figure 2c ). These data are representative of 3 independent experiments and similar results have been obtained on CLL cells purified from 10 different patients. Finally, we measured cell survival in the presence of either Ly294002 or UO126 (a mitogenactivated protein kinase/extracellular signal-regulated kinase (MEK) inhibitor; Figure 2d ). medium alone, with the only exception of cells treated with CXCL13 in the presence of Ly294002. Thus it appears that chemokine-induced cell survival requires both ERK and PI3K pathways.
Chemokines enhance Akt-mediated phosphorylation of FOXO3a in B-CLL cells FOXO3a, a target of Akt, belongs to the Forkhead superfamily of transcription factors implicated in cell proliferation, differentiation and survival. In the presence of survival factors, FOXO3a is phosphorylated by Akt and sequestrated by 14-3-3 proteins in the cytosol, which prevents its nuclear translocation and thus activation of target genes (Birkenkamp and Coffer, 2003; Burgering and Medema, 2003) . As shown in Figure 3a , FOXO3a was constitutively phosphorylated on its major Akt site, Threonine 32, in B-CLL cells from 14 patients out of 15. We found that homeostatic chemokines treatment of B-CLL cells increased further the phosphorylation of FOXO3a on Thr32 (Figure 3b ).
A time course performed with CXCL12 ( Figure 3c ) shows that FOXO3a was phosphorylated 1 min after stimulation, a kinetic compatible with the kinetics of Akt phosphorylation. The phosphorylation of FOXO3a was strongly inhibited by the preincubation of leukemic cells with Ly294002 ( Figure 3c ). These experiments are representative of experiments performed on CLL cells purified from 10 different patients. GSK3 represents another well-characterized Akt substrate (Eldar-Finkelman, 2002) . We therefore monitored the phosphorylation status of GSK3 as an additional control of Akt activation in CLL cells following CXCL12 treatment. Similar to FOXO3a, the phosphorylation of GSK3 a/b Akt sites was increased upon CXCL12 treatment and blocked by Ly294002 (Figure 3c ). Finally, glutathione-S-transferase (GST)-14-3-3 fusion proteins pull-down experiments on lysates of B-CLL cells activated or not with CXCL12 showed that phosphorylated FOXO3a associated with 14-3-3 proteins. This interaction was abrogated in cells treated by Ly294002 (Figure 3d ). These data are representative of two independent /ml) were preincubated with medium, Ly294002 (25 mM) or U0126 (12.5 mM) for 3 h, then activated at 371C for 5 min with PMA (0.1 mg/ml), CXCL12 (0.1 mg/ ml), CCL21 (1 mg/ml), CCL19 (1 mg/ml), CXCL13 (1 mg/ml) or medium. Cell lysates were then analysed by immunoblotting using anti phospho-Ser473 Akt antibodies. Membranes were stripped and reblotted with anti-Akt antibody. (b) Purified leukemic B cells (10 7 /ml) from one representative patient were preincubated with medium or Ly294002 (25 mM) for 3 h, then activated for different time periods with CXCL12 (0.1 mg/ml). Membranes were blotted using anti phospho-Akt or phospho-p90RSK antibodies before being stripped and reblotted with an anti-Akt antibody or an anti-ERK2 as loading control. (c) Same experiment as in panel a except that anti-BCR stimulation was used instead of CCL19. Membranes were blotted with either anti-phospho-ERK1/2 or phospho-p90RSK antibodies. Protein loading was controlled by anti-ERK2 and anti-b-actin blotting. (d) B-CLL cells purified from seven patients (10 6 /ml) were preincubated with Ly294002 (12.5 mM) or U0126 (12.5 mM) for 3 h, then cultured in the presence or not of PMA, CXCL12, CCL21, CXCL13 for 72 h. Cell survival was measured by annexin-V/PI staining and represented the mean of triplicate determinations. The P-value (n ¼ 7) is shown at the top of each histogram. ERK, extracellular signal-regulated kinase; PI, propidium iodide; PMA, phorbol myristate acetate.
experiments and similar results have been obtained on CLL cells purified from three different patients. These results indicate that in B-CLL cells chemokines enhance the phosphorylation of Akt, which in turn phosphorylates FOXO3a allowing its interaction with 14-3-3 proteins, an event associated with a decreased proapoptotic activity of FOXO3a.
Expression of a constitutively activated FOXO3a mutant induces apoptosis in CLL
We examined the effect of CXCL12 treatment on the transcriptional activation of a Bim-luciferase reporter construct transfected in CLL cells. As shown in Figure 4a , CXCL12 treatment resulted in an important decrease of Bim-luciferase activity, indicating that CXCL12 may affect the transcriptional activity of endogenous FOXO3a in CLL cells. These data are representative of experiments obtained on CLL cells purified from three different patients. We next overexpressed in primary B-CLL cells a mutated form of FOXO3a, FOXO3a TM (TM for triple mutant) tagged with green fluorescent protein (GFP). This mutant is unable to be phosphorylated by Akt on Thr32, Ser 253 and Ser315 residues, and thus acts as a constitutively active protein (Brunet et al., 1999) . We used an electroporation strategy, which consistently resulted in, up to 30% of cells transfected with GFP-FOXO3a and showing high levels of expression (high, 17%) and low levels of expression (low, 13%; Figure 4b ). Sub-cellular localization of GFP-FOXO3a TM protein was also assayed by confocal microscopy (Figure 4c ). Cotransfection of forkhead-responsive element (FRE) or Bim promoter reporter constructs with plasmids encoding either GFP-FOXO3a TM or GFP alone showed that GFP-FOXO3a TM was functional in CLL cells, as shown by increased luciferase activities measured 18 h after transfection (Figure 4d ). Cells transfected with GFP-FOXO3a TM or GFP alone were cultured in the presence of CXCL12 or medium alone for different periods of time. Cells were then labeled with Annexin V-FITC/propidium iodide (PI) and the fraction of GFP þ cells undergoing apoptosis was studied by flow cytometry (Figure 4e ). In cells expressing high levels of GFP-FOXO3a TM (left panel), survival induced by CXCL12 was almost abolished, as compared to cells expressing low levels of GFP-FOXO3a TM (right panel). By contrast, CXCL12 increased survival in GFP-transfected cells. These data are representative of experiments obtained on CLL cells purified from three different patients. These results show that the survival effect triggered by chemokines is dramatically reduced when a form of FOXO3a mutated on Akt sites is expressed in CLL cells. ) were preincubated with or without Ly294002 for 3 h, then stimulated with CXCL12 (0.1 mg/ml) for 1 min at 371C. Lysates were incubated with GST or GST-14-3-3t fusion proteins, and glutathione-sepharose beads. Precipitates were then analysed by immunoblotting with anti-phospho-FOXO3a antibodies. Input protein quantities were controlled by anti-FOXO3a blotting of total cell lysates. B-CLL, B-chronic lymphocytic leukemia; GST, glutathione-S-transferase; PMA, phorbol myristate acetate.
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Suppression of FOXO3a expression enhances CLL spontaneous cell survival and diminishes chemokineinduced resistance to apoptosis Finally, we used siRNA directed against FOXO3a to suppress its expression in CLL cells. Cells were treated as above except that they were co-transfected with a pool of siRNA directed against FOXO3a and a fluorescent siRNA (siGLO) or control siRNA and fluorescent siRNA. Cells co-transfected with fluorescent siRNA were easily detectable as compared to cells electroporated in medium only (Figure 5a ). After transfection, cells were kept in culture medium for 24 h to obtain a significant decrease of FOXO3a expression on siGLO þ purified cells (Figure 5b ). CXCL12 was then added or not in the medium for different periods of time and cell survival was evaluated by flow cytometry as described above. As shown in Figure 5c , addition of CXCL12 for 48 or 72 h enhanced cell survival in CLL cells transfected with control siRNAs. By contrast, in cells transfected with siRNAs against FOXO3a, the reduction of FOXO3a expression significantly enhanced basal cell survival both at 48 and 72 h, whereas it almost abolished the increase of cell survival observed following CXCL12 treatment. These data are representative of experiments obtained on CLL cells purified from three different patients. Together, these results indicate that FOXO3a plays a key role in spontaneous CLL cell survival and in chemokine-induced cell survival.
Discussion
It is known for long that microenvironment favors the growth and survival of malignant lymphocytes in CLL. In this work, we show that homeostatic chemokines, CXCL12, CXCL13, CCL21 and CCL19, which are all 
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Bim 10 expressed by lymph nodes and involved in the physiological trafficking of B cells also provide strong survival signals to leukemic cells from B-CLL mainly through the inactivation of the proapoptotic transcription factor FOXO3a. Our results also indicate that spontaneous and chemokine-induced leukemic cells survival requires Akt-dependent inactivation of FOXO3a.
The chemokines tested in this study are likely to interact with leukemic cells in vivo, as they are all expressed in lymph nodes and play a critical role for B-cell entry into lymph nodes and Peyer's patches (Okada et al., 2002) . Recent data also show that chemokines participate in CLL resistance to apoptosis. Blood-derived nurse-like cells enhance leukemic cell survival through both production of CXCL12 and additional factors such as BAFF or APRIL (Burger et al., 2000; Nishio et al., 2005) , whereas use of blocking peptides directed against CXCR4 inhibited a wide range of CXCL12 functions in CLL, including apoptosis (Burger et al., 2005) . These results and ours fit well with the current notion that chemokines in addition to their role in cell trafficking play broader functions in cellular physiology and physiopathology. It is noteworthy that homeostatic chemokines are present in multiple microenvironments such as bone marrow or secondary lymphoid organs like spleen or mucosal-associated lymphoid tissue. Whether other homeostatic chemokines specific to these locations or other extrinsic factors could act in concert to provide survival signals to leukemic cells remains to be determined.
We addressed the question of how these homeostatic chemokines mediate cell survival in CLL. The Ras/Raf/ MEK/ERK MAP kinase pathway has been involved in several cellular responses, including apoptosis (Baccarini, 2002) . In CLL, Pepper et al. (2003) reported that EB1089, a vitamin D3 analog induces apoptosis in B-CLL via suppression of ERK activity. In addition, inhibition of this pathway induces apoptosis in different hematopoietic cells such as the murine erythroleukemia SKT6 cells (Nagata and Todokoro, 1999) , normal erythroid progenitor cells (Mori et al., 2003) or in hairy cells of hairy-cell leukemia (HCL) (Kamiguti et al., 2003) . However, while ERK1/2 is constitutively phosphorylated in HCL, in CLL cells purified from three patients, ERK1/2 phosphorylation was absent in two cases and only weakly present in the third (Kamiguti et al., 2003) . These results are consistent with our data showing no or little constitutive phosphorylation of ERK1/2. By contrast, CLL cells treatment with UO126 inhibited the survival effect promoted by chemokines and completely abrogated the phosphorylation of ERK1/2. Interestingly, the level of ERK and p90RSK activation was lower in cells treated by LY294002 than in untreated cells, suggesting that in B-CLL cells two pathways lead to ERK activation by chemokines, one being partially dependent on PI3K activity. A previous work showed that CXCL12 induces the phosphorylation of ERK1/2 in CLL (Burger et al., 2000) . Our study further extends this observation to other homeostatic chemokines, namely CCL21, CCL19 and CXCL13, establishing that chemokine-induced CLL cell survival is in part mediated through MAPK pathway activation.
In this study, we have also investigated the implication of the PI3K/Akt pathway in chemokine-induced leukemic cell survival. The PI3K/Akt pathway has emerged during the past years as a key regulator of multiple cellular processes including proliferation, differentiation, metabolism and apoptosis, and several components of this pathway are dysregulated in several human cancers (Vivanco and Sawyers, 2002) . However, its role in B-CLL cell survival is still unclear. We found that Akt is constitutively phosphorylated in B-CLL cells from 15 patients and that chemokines treatment further increases its phosphorylation in a PI3K-dependent manner, suggesting that Akt activity participates to the regulation of both spontaneous and chemokine-induced cell survival. In addition, Ly294002 significantly decreased chemokine-induced cell survival, with the only exception of CXCL13 treatment. This data seems to be contradictory with a previous study showing that PI3K-dependent B-CLL cell survival relied on PKCd activation rather than Akt (Ringshausen et al., 2002) . The explanation for this discrepancy is unclear and may come from different experimental approaches. However, in our study, constitutive Akt phosphorylation was directly assessed by comparison to chemokine, PMA and anti-BCR treatment. In addition, PTEN (phosphatase and tensin homolog deleted in chromosome 10) which negatively regulates the PI3K/Akt pathway, is absent or diminished in almost 50% of CLL (Leupin et al., 2003) . Although other mechanisms cannot be excluded, the absence of such a negative control is likely to account for a significant fraction of the sustained Akt phosphorylation found in leukemic cells from our study.
One major way by which Akt mediates cell survival is through the phosphorylation and inactivation of Forkhead box class O (FOXO) proteins, a family of transcription factors regulating cell proliferation and survival, and stress responses (Brunet et al., 1999; Birkenkamp and Coffer, 2003; Burgering and Medema, 2003) . In hematopoietic cells, two major members, FOXO1 and FOXO3a, represent the FOXO family. Because the phosphorylation status of FOXO3a has been linked to increased resistance to cell death in a number of hematopoietic cells, we hypothesized that FOXO3a may represent an important regulator of B-CLL cell survival. Indeed, we found that FOXO3a is constitutively phosphorylated on its Akt target site Thr32 in B-CLL cells. All homeostatic chemokines tested in this study increase the phosphorylation of FOXO3a on its Akt sites. This phosphorylation is largely Akt-dependent, with a kinetic fully compatible with chemokine-induced Akt phosphorylation, and it is largely inhibited by cell preincubation with the PI3K inhibitor LY294002. In addition, we observed that FOXO3a was constitutively associated with 14-3-3 proteins and that this interaction was enhanced following cell stimulation with CXCL12. This event is likely to prevent its nuclear localization and thus activation by FOXO3a of proapoptotic target genes. Finally, the expression in B-CLL cells of a form of FOXO3a mutated on all Akt phosphorylation sites or siRNAmediated suppression of FOXO3a expression dramatically decreased CXCL12-induced cell survival. Overall, these data support the notion that a large part of the anti-apoptotic effect mediated by chemokines in CLL is FOXO3a-dependent.
Interestingly, we observed that inhibition of FOXO3a expression also increases spontaneous cell survival, suggesting that a significant part of spontaneous CLL cell survival can be mediated through intrinsic modulation of FOXO3a phosphorylation/inactivation. Whether this process stems from aberrant Akt activity downstream PI3K (Ringshausen et al., 2002) and/or PTEN (Leupin et al., 2003) signaling remains to be determined. In our hands, pharmacological inhibition of PI3K in CLL does not completely decrease constitutive FOXO3a phosphorylation, suggesting the existence of PI3K-independent mechanisms. Indeed, in human breast tumors, the cytoplasm sequestration of FOXO3a has been reported to rely on the phosphorylation of FOXO3a Serine 644 residue by IKKb (inhibitor of NF-kB kinase b; Hu et al., 2004) , a process that remains to be investigated in CLL.
In conclusion, our work shows that homeostatic chemokines, which are constitutively expressed in the different microenvironments leukemic cells circulate within, are involved in B-CLL survival through activation of MAPK and PI3K/Akt pathways. Our data also demonstrate and emphasize the role of inactivation FOXO3a in both constitutive and chemokine-induced B-CLL cell resistance to apoptosis and suggests that it might constitute a therapeutic target in this disease.
Materials and methods
Patients
Peripheral blood samples were obtained from 26 patients with B-CLL. All the patients included in this study gave their informed consent according to the Institutional Review Board at the Centre Hospitalier Universitaire of Nice. Diagnosis of B-CLL was based on clinical and immunophenotypic criteria. Patients included in this study were either untreated or had not received chemotherapy or steroids for a period of at least 3 months before the investigation.
Reagents, antibodies and plasmid constructs
The chemokines used in this study (CXCL12, CCL21, CCL19 and CXCL13) were obtained from R&D Systems (Abingdon, UK). The following antibodies: anti-PE-CXCR4, -CCR7, -CXCR5 monoclonal antibody (mAb) were from R&D Systems; antiIgM was from DakoCytomation (Trappes, France); anti-FITC-CD5, anti-APC-CD19, anti-PE-CD38, -CD56, -CD3 and anti-PE isotype mouse control IgG were from BectonDickinson (San Jose, CA, USA); anti-ZAP-70 was obtained from Upstate (Charlottesville, VA, USA), IgG2a isotype control and FITC-GAM were from Pharmingen (San Diego, CA, USA); anti-phospho-ERK1/2, anti-phospho-Akt, antiAkt, anti-phospho-FOXO3a, anti-FOXO3a, anti-phosphoGSK3a/b polyclonal antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA) and anti-GSK3b was purchased from Alexis (San Diego, CA, USA). PMA was obtained from Sigma (St Louis, MI, USA), Ly294002 and U0126 were from Cell Signaling. Pools of four siRNA duplexes directed against FOXO3a, control siRNAs, fluorescent siRNAs (used in co-transfection experiments) were from Dharmacon (Lafayette, CO, USA). FRE and Bim promoter luciferase reporter constructs were a generous gift from Anne Brunet (San Franscisco, CA, USA) and Eric W Lam (London, UK), respectively. The GST-14-3-3t plasmid was kindly provided by Y-C Liu (San Diego, CA, USA). To generate N-terminal GFP-tagged FOXO3a TM constructs, the cDNAs encoding FOXO3a TM was amplified from pcDNA3 HAFOXO3a TM (Charvet et al., 2003) by PCR using the following oligonucleotide primers: forward, 5 0 -catctcgagatgg cagaggcaccggc-3 0 ; reverse, 5 0 -gtcggatccgcctggcacccagctctg-3 0 . Following digestion with XhoI and BamHI, the PCR products were cloned into pEGFP-C3 vector (Clontech, Palo Alto, CA, USA) and sequenced.
Cell preparation, culture and apoptosis assay Peripheral mononuclear cells were isolated from peripheral blood by Ficoll-Hypaque density gradient centrifugation. Leukemic B cells were then isolated by magnetic selection using magnetic beads (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) according to the manufacturer's instructions. B-cell purity was >98%. After purification, cells were cultured at the concentration of 1 Â 10 6 /ml for 24 or 72 h in RPMI containing 10% fetal calf serum (FCS), 1 mM Lglutamine, 1 mM pyruvate. Chemokines were added at the initiation of the culture at the following concentrations: CXCL12 100 ng/ml and CCL21, CCL19, CXCL13 at 1 mg/ ml. Note that these chemokine concentrations were also found to induce the maximal migration indice of B-CLL cells in a cell migration assay (data not shown; Ticchioni et al., 2002) . When used, inhibitors were first added 3 h before chemokines. The evaluation of living cells was done by double staining with annexin V-FITC and PI according to the manufacturer's instructions (BD Biosciences, San Diego, CA, USA) and analysis was made by flow cytometry (FACSCalibur, BectonDickinson) . In transfection experiments, we used annexin V-PE purchased from the same manufacturer (BD Biosciences).
Cell transfection and reporter assays Transient transfections into human B-CLL cells were performed using the AMAXA nucleofection system (AMAXA GmbH, Germany) according to the manufacturer's instructions. Briefly, cells were thawed and cultured for 18 h in RPMI-1640 medium supplemented with 10% FCS and glutamine. CLL cells (10 7 ) were washed and resuspended in 100 ml of Buffer V (AMAXA), mixed with 10-15 mg of plasmid DNA or 1 mM of siRNA duplex (control or against FOXO3a) and electroporated using program U-15 on AMAXA nucleofector device. Cells were rapidly transferred to 371C preheated medium and incubated for 24-72 h at 371C, 5% CO 2 .
Luciferase reporter assays were performed according to the manufacturer's protocol (Promega, Madison, WI, USA) on lysates from B-CLL cells transfected with pEGFP or pEGFPFOXO3aTM vectors, and the indicated reporter plasmid. Luciferase activities were measured using a luminometer (EG&G Berthold; PerkinElmer Life Sciences, Waltham, MA, USA). Normalization of transfection efficiency was performed by gating on GFP-positive cells. Normalized luciferase activities were determined in triplicate and expressed as fold increase relative to the basal activity seen in pEGFP vector-transfected cells.
Immunoblot analysis and GST pull-down assay GST-14-3-3t fusion proteins were produced as described previously (Charvet et al., 2003) . Cells (10 7 /ml) in RPMI containing 10% FCS, and 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.5), were stimulated at 371C for the indicated time with different chemokines in the presence or not of pharmacological inhibitors. Activation was stopped by the addition of 1 ml of ice-cold stop buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 100 mM NaF, 10 mM EDTA, 10 mM Na 4 P 2 O 7 and 2 mM Na 3 VO 4 ). After centrifugation, cells were resuspended in ice-cold lysis buffer (1% Triton X-100 in 150 mM NaCl, 50 mM HEPES (pH 7.4), 5 mM NaF, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride) for 30 min. Lysates were clarified by centrifugation at 15 000 g for 15 min at 41C. For GST pulldown, lysates were incubated with 5 mg of GST-14-3-3t for 3 h at 41C, followed by incubation with glutathione-sepharose 4B beads (Pharmacia, GE Healthcare, Uppsala, Sweden) for 1 h before being washed three times in lysis buffer. Whole-cell lysates or precipitates were then separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), transferred to nitrocellulose filters and analysed by immunoblotting using enhanced chemiluminescence (Amersham, GE Healthcare).
Measurement of CD38 and ZAP-70 expression ZAP-70 expression was determined by flow cytometry on thawed lymphoid cells as described previously (Crespo et al., 2003) . Briefly, cells were first fixed and permeabilized using the Fix & Perm kit according to the manufacturer's instructions (Caltag Laboratories, Burlingame, CA, USA), then incubated either with an anti-ZAP or an isotype control antibody followed by secondary antibody (FITC-GAM), before being incubated with PE-CD56, PE-CD3 and APC-CD19 mAbs. A CLL was considered as ZAP-70-positive, when more than 20% of the CD19 cells expressed ZAP-70. CD38 expression was measured by a three-color flow cytometry technique as described previously (Durig et al., 2002) .
IgHV mutational status
Analysis of IgHV genes was performed on leukemic cells obtained from peripheral blood after Ficoll Hypaque centrifugation. Briefly, amplification of immunoglobulin heavychain variable regions by PCR was performed on DNA with consensus primers for the VH framework region 1 and JH genes (Aubin et al., 1995) or following the BIOMED-2 protocols (van Dongen et al., 2003) . Purified PCR products were sequenced either directly or after a cloning procedure using an automated DNA sequencer. Sequence data were analysed using IgBLAST (http://www.ncbi.nlm.nih.gov/ igblast) and the ImMunoGeneTics database (IMGT, http:// imgt.cines.fr). The sequences having 98% or higher homology with the closest germline counterpart were considered unmutated, and those with a homology less than 98% as mutated.
Statistical analysis
Statistical significances were determined using the non-parametric Wilcoxon-signed rank test and the Mann-Whitney test as appropriate. Po0.05 was considered to be statistically significant. Data from groups of patients are expressed as mean7s.d., whereas data from individual experiments are expressed as mean7s.e.m.
